Mirion Technologies Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $258 million, up 28% year-over-year.

Organic Revenue Growth: 3%, consistent with expectations.

Adjusted EBITDA: $54 million, reflecting a 16% increase from the prior year.

Adjusted EPS: $0.10 per share.

Orders: Increased 42% to $288 million, with core orders growing nearly 20%.

Backlog: Expanded to $1.1 billion, up 19% excluding M&A, and 38% including M&A.

2Strategic Updates and Business Highlights

Nuclear Power Segment: Strong demand driven by existing reactors and small modular reactors (SMRs). Notable orders included $50 million from large opportunity orders in Q1 and an additional $35 million in April.

Paragon and Certrec Acquisitions: Contributed significantly to order growth and revenue. Paragon's revenue grew 45% in Q1, enhancing Mirion's market position.

Medical Segment: Positive momentum with a significant order from Varian for radiation-hardened cameras. Expecting double-digit organic growth in Nuclear Medicine for 2026.

Integration Progress: Successful cultural alignment and operational integration with Paragon, with early signs of commercial synergies.

3Forward Guidance and Outlook

Q2 Expectations: Anticipating 15% to 20% sequential order growth. Organic revenue growth expected to remain in the low single digits.

2026 Guidance: No changes to revenue or EBITDA guidance, with continued confidence in achieving double-digit growth in Nuclear Power and maintaining adjusted EBITDA margins.

Long-term Goals: Commitment to a 30% adjusted EBITDA margin target by 2028, with a focus on operational efficiencies and leveraging AI technologies.

4Bad News, Challenges, or Points of Concern

Margin Compression: Adjusted EBITDA margins contracted due to M&A dilution and a mix shift within the Nuclear & Safety segment.

Cash Flow: Generated $11 million in adjusted free cash flow, historically the weakest quarter for cash generation. Concerns about working capital dynamics impacting cash flow.

Market Risks: Ongoing geopolitical tensions and reliance on energy availability could pose risks to growth projections, particularly in the context of nuclear energy's role in energy security.

5Notable Q&A Insights

Nuclear Market Dynamics: CEO Tom Logan highlighted a significant shift in the nuclear industry's approach, moving from shutdowns to long-term operational strategies, creating a favorable environment for Mirion.

Medical Business Confidence: CFO Brian Schopfer expressed increased confidence in the Medical segment's growth potential, particularly following the Varian order, though caution remains regarding Asian market performance.

Backlog and Revenue Visibility: Analysts inquired about the visibility into 2027 based on backlog growth, with management indicating confidence in sustained order momentum and revenue opportunities. Overall, Mirion Technologies demonstrated strong performance in Q1 2026, with significant order growth and strategic advancements, while also addressing challenges related to margins and cash flow dynamics. The outlook remains positive, bolstered by favorable market conditions in the nuclear sector and ongoing integration efforts with recent acquisitions.